Last mentioned: Mar 6, 2026
Phase I Milestone
First human subject enrolled and dosed in the Phase I clinical trial.
AI Discovery
Insilico Medicine identifies ISM4808 using its Pharma.AI platform.
Out-Licensing
TaiGen Biotechnology secures rights for the clinical development of the candidate.
Insilico Medicine and TaiGen have successfully enrolled and dosed the first human subject in a Phase I clinical trial for ISM4808, a novel drug candidate for Chronic Kidney Disease (CKD) anemia. The milestone validates the clinical transition of an AI-discovered molecule under a strategic out-licensing agreement.
This page surfaces every story mentioning Insilico Medicine across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Insilico Medicine was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |